A
Andrew J. Wyrobek
Researcher at Lawrence Berkeley National Laboratory
Publications - 166
Citations - 12449
Andrew J. Wyrobek is an academic researcher from Lawrence Berkeley National Laboratory. The author has contributed to research in topics: Sperm & Aneuploidy. The author has an hindex of 56, co-authored 166 publications receiving 11927 citations. Previous affiliations of Andrew J. Wyrobek include University of California, Berkeley & Lawrence Livermore National Laboratory.
Papers
More filters
Journal ArticleDOI
Chemical induction of sperm abnormalities in mice.
Andrew J. Wyrobek,W R Bruce +1 more
TL;DR: The results suggest that sperm abnormalities might provide a rapid inexpensive mammalian screen for agents that lead to errors in the differentiation of spermatogenic stem cells in vivo and thus indicate agents which might prove to be mutagenic, teratogenic, or carcinogenic.
Journal ArticleDOI
Effects of male age on semen quality and fertility: a review of the literature
TL;DR: The weight of the evidence suggests that increased male age is associated with a decline in semen volume, sperm motility, and sperm morphology but not with sperm concentration.
Journal ArticleDOI
Smoking and low antioxidant levels increase oxidative damage to sperm DNA.
TL;DR: The possibility that paternal smoking causes mutations in sperm that lead to cancer, birth defects, and genetic diseases in offspring is discussed.
Journal ArticleDOI
An evaluation of the mouse sperm morphology test and other sperm tests in nonhuman mammals: A report of the U.S. environmental protection agency Gene-Tox program
Andrew J. Wyrobek,Laurie Gordon,James G. Burkhart,Mary W. Francis,Robert W. Kapp,Gideon Letz,Heinrich V. Malling,John C. Topham,M.Donald Whorton +8 more
TL;DR: The mouse sperm morphology test has potential use for identifying chemicals that induce spermatogenic dysfunction and perhaps heritable mutations, and is found to be highly sensitive to germ-cell mutagens.
Journal ArticleDOI
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
Olga K. Mirzoeva,Debopriya Das,Laura M. Heiser,Sanchita Bhattacharya,Doris R. Siwak,Rina Gendelman,Nora Bayani,Nicholas J. Wang,Richard M. Neve,Yinghui Guan,Zhi Hu,Zachary A. Knight,Heidi S. Feiler,Philippe Gascard,Bahram Parvin,Paul T. Spellman,Kevan M. Shokat,Andrew J. Wyrobek,Mina J. Bissell,Frank McCormick,Wen Lin Kuo,Gordon B. Mills,Joe W. Gray,W. Michael Korn +23 more
TL;DR: These findings enhance the understanding of the interconnectivity of oncogenic signal transduction circuits and have implications for the design of future clinical trials of MEK inhibitors in breast cancer by guiding patient selection and suggesting rational combination therapies.